Sunday, January 6, 2013

NHS in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D) (NASDAQ:VRTX)

NHS in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D) (NASDAQ:VRTX)

What Is The Relationship Between The US Actor Jack Klugman And Orphan Drugs ? « Orphan Druganaut Blog

What Is The Relationship Between The US Actor Jack Klugman And Orphan Drugs ? « Orphan Druganaut Blog

CANADIAN ORGANIZATION FOR RARE DISORDERS (CORD) | Canadian Organization for Rare Disorders Welcomes Announcement of Orphan Drug Framework

CANADIAN ORGANIZATION FOR RARE DISORDERS (CORD) | Canadian Organization for Rare Disorders Welcomes Announcement of Orphan Drug Framework

Canadian Organization for Rare Disorders

Canadian Organization for Rare Disorders

Terrific News For Rare Diseases And Orphan Drugs In Canada « Orphan Druganaut Blog

Terrific News For Rare Diseases And Orphan Drugs In Canada « Orphan Druganaut Blog